Mid-Afternoon Market Update: US Stocks Mostly Flat; DiaMedica Therapeutics Shares Plunge
June 29, 3:01 PM
Toward the end of trading Tuesday, the Dow traded up 0.04% to 34,295.41 while the NASDAQ rose 0.13% to 14,518.98. The S&P traded flat at 4,290.65.
Mid-Day Market Update: Gold Drops Over 1%; Cerevel Therapeutics Shares Spike Higher
June 29, 12:18 PM
Midway through trading Tuesday, the Dow traded up 0.37% to 34,411.60 while the NASDAQ fell 0.03% to 14,495.75. The S&P also rose, gaining 0.16% to 4,297.63.
Mid-Morning Market Update: Markets Mostly Higher; FactSet Research Reports Mixed Q3 Results
June 29, 10:16 AM
Following the market opening Tuesday, the Dow traded up 0.40% to 34,420.32 while the NASDAQ fell 0.10% to 14,486.23. The S&P also rose, gaining 0.14% to 4,296.59.
A Peek Into The Markets: US Stock Futures Mixed After S&P 500 Hits New High
June 29, 6:03 AM
Pre-open movers
Mid-Afternoon Market Update: Nasdaq Gains 100 Points; New Senior Investment Shares Spike Higher
June 28, 2:40 PM
Toward the end of trading Monday, the Dow traded down 0.49% to 34,266.49 while the NASDAQ rose 0.72% to 14,463.26. The S&P also rose, gaining 0.05% to 4,283.04.
Mid-Day Market Update: Crude Oil Down Over 1%; Intellia Therapeutics Shares Jump
June 28, 12:22 PM
Midway through trading Monday, the Dow traded down 0.52% to 34,253.86 while the NASDAQ rose 0.72% to 14,463.56. The S&P also fell, dropping 0.01% to 4,280.50.
Mid-Morning Market Update: Markets Mixed; Perion Network Boosts FY21 Outlook
June 28, 10:08 AM
Following the market opening Monday, the Dow traded down 0.30% to 34,329.01 while the NASDAQ rose 0.60% to 14,446.74. The S&P also rose, gaining 0.04% to 4,282.58.
A Peek Into The Markets: US Stock Futures Mixed; Crude Oil Edges Lower
June 28, 6:09 AM
Pre-open movers
Regeneron’s and Sanofi’s Dupixent SmPC Updated With Long-term Data Reinforcing Well-established Safety Profile in Adults With Moderate-to-severe Atopic Dermatitis
June 28, 5:40 AM
Long-term safety data from a study of adults with moderate-to-severe atopic dermatitis treated with Dupixent will be added to the Dupixent Summary of Product Characteristics (SmPC) following a positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use.